Financial disclosures for the Practice Management Committee

Practice Management Committee - Financial Interest Disclosures

Disclosures

ASRS adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The individuals below have responded that they have no relevant financial relationships with commercial entities:

  • Geeta Lalwani, MD
  • Nader Moinfar, MD, MPH, FACS, FASRS
  • Gayatri Reilly, MD

The individuals below have disclosed the following financial relationships with commercial interests (commercial interest/type of relationship/compensation): All of the relevant financial relationships listed for these individuals have been mitigated.

  • Margaret Chang, MD, MS – Genentech – Consultant; RegenXBio – Consultant; Opthea – Principle Investigator; Novartis – Principal Investigator; Allergan – Principal Investigator; Mylan – Principal Investigator; Ophthotech – Principal Investigator; NGM – Principal Investigator.
  • Sabin Dang, MD – Regeneron – Speaker Bureau; Bausch & Lomb – Principal Investigator.
  • Anton Orlin, MD – Eyepoint Pharma – Advisory Board Member; Genentech – Advisory Board Member; Allergan; Advisory Board Member.
  • Ankoor Shah, MD, FASRS – RegenexBio – Consultant; Bausch+Lomb - Consultant.
  • Charles Wykoff, MD, PhD, FASRS – AbbVie – Consultant; Adverum – Consultant/Principal Investigator; Aerie – Consultant/Principal Investigator; Aldeyra – Principal Investigator; Alimera – Consultant/Principal Investigator; Alkahest – Principal Investigator; Allergan – Consultant/Principal Investigator; Allgenesis – Consultant; Alnylam – Consultant; Amgen – Principal Investigator; Annexon – Consultant/Principal Investigator; Apellis – Consultant/Principal Investigator; Arrowhead – Consultant; Asclepix – Principal Investigator; Bausch+Lomb – Consultant; Bayer – Consultant/Principal Investigator; Bionic Vision Technologies – Consultant; Boehringer Ingelheim – Principal Investigator; Chengdu Kanghong Biotechnologies – Consultant; Chendu Kanghong Biotechnology – Principal Investigator; Cholgene – Consultant; Clearside – Consultant/Principal Investigator; Eye Point – Consultant; Gemini – Principal Investigator; Genentech – Consultant/Principal Investigator; Graybug – Principal Investigator; Gyroscope – Consultant/Principal Investigator; IONIS – Principal Investigator; IRENIX – Principal Investigator; IVERIC Bio – Consultant/Principal Investigator; Janssen – Consultant; Kato – Consultant; Kodiak – Consultant/Principal Investigator; LMRI – Principal Investigator; Merck – Consultant; Nanoscope – Principal Investigator; Neurotech – Principal Investigator; NGM – Consultant/Principal Investigator; Novartis – Consultant/Principal Investigator; OccuRx – Consultant; Ocular Therapeutix; Consultant/Principal Investigator; OliX- Consultant; ONL – Consultant/Stock Options; Opthea – Consultant/Principal Investigator; Oxurion – Principal Investigator; Palatin – Consultant; Perfuse – Consultant; PolyPhotonix – Stock Options/Consultant; Ray – Consultant; RecensMedical – Consultant/Principal Investigator/Stock Options; Regeneron – Consultant/Principal Investigator; RegenXBio- Consultant/Principal Investigator; Roche – Consultant/Principal Investigator; SamChunDang Pharm – Principal Investigator; Stealth – Consultant; Surrozen – Consultant; Taiwan Liposome Company – Principal Investigator; Takeda – Consultant; THEA – Consultant; Valo – Consultant; Visgenx – Stock Options; Vitranu – Stock Options; Xbrane – Principal Investigator